CURE’s neuroendocrine cancer page features the latest cancer news and updates on neuroendocrine cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in neuroendocrine cancer.
April 23rd 2024
Lutathera was approved for patients 12 or older with SSTR-positive gastroenteropancreatic neuroendocrine tumors, the FDA announced.